Integrated approach for the preoperative correction of anemia for liver resection in patients with colorectal liver metastases

Abstract

Aim. To study the features of the pathogenesis of anemia in patients with colorectal cancer and metastatic liver damage, as well as to evaluate the effectiveness of etiological correction of anemia in the preoperative period.

Methods. 90 patients with colorectal liver metastases and anemia (hemoglobin content 75–95 g/L), who were observed at the City Clinical Oncological Center of St. Petersburg between 2014 and 2020, were included. The patients were divided into two groups. The first group consisted of prospectively assessed patients with the preoperative correction of anemia by iron supplements (intravenously 7 mg/kg once a week) and recombinant erythropoietin (subcutaneously 150 IU/kg 3 times a week). The second group included retrospectively assessed patients with the correction of anemia only by red blood cell (RBC) transfusion (1–3 doses). The groups were comparable for gender [sex ratio (male/female) was 17:31 and 16:26 for the first and the second groups, respectively; p >0.5], age (63.3±1.4 and 60.2±1.2 years, respectively; p >0.1) and hemoglobin content (87.4±1.0 and 86.7±0.9 g/l, respectively; p >0.2).

Results. In studying the causes of anemia, a decrease in the mean serum endogenous erythropoietin level was revealed in most patients (36.7±1.9 mIU/ml with the required 70 mIU/ml). A decrease in the concentration of serum iron (6.6±0.3 versus 15.1±0.8 μmol/l) and ferritin (15.5±1.9 versus 102.4±8.4 μg/ml) levels were revealed. At the same time, there was no difference in the concentration of pro-inflammatory cytokines in patients with anemia and healthy controls (tumor necrosis factor α, interleukin-1β, interleukin-6; p >0.2), which indicates a low activity of the immune system in response to a tumor, due to conducted chemotherapy. In the preoperative correction of anemia, a positive effect was achieved with both iron supplementation with erythropoietin preparation (the hemoglobin level increased from 87.6±1.0 to 108.1±0.9 g/l; p <0.01) and RBC transfusion (from 86.7±0.9 to 114.6±0.6 g/l; p <0.01).

Conclusion. In patients with colorectal liver metastases, the most common causes of anemia were low levels of erythropoietin and iron deficiency; also for this group of patients, the prescription of erythropoietin and intravenous iron preparations are effective for the preoperative correction of anemia.

Keywords

anemia / colorectal cancer / liver metastases / erythropoietin / iron supplements / erythrocyte transfusion / liver resection

References

[1] Davydov M.I., Axel E.M. Statistics of malignant neoplasms in Russia and CIS countries in 2009. Vestnik RONTs im. N.N. Blokhina RAMN. 2011; 22 (3, ­suppl. 1): 85. (In Russ.)

[2] Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Вестн. РОНЦ им. Н.Н. Блохина РАМН. 2011; 22 (3, прил. 1): 85.

[3] Patyutko Yu.I., Sagaidak I.V., Polyakov A.N. et al. Surgery and chemotherapy plus surgery for patients with colorectal cancer liver metastases. Tazovaya khirurgiya i onkologiya. 2011; (1): 32–40. (In Russ.) DOI: 10.24412/Fhr0i8_-Ots.

[4] Патютко Ю.И., Сагайдак И.В., Поляков А.Н. и др. Хирургическое и комбинированное лечение больных колоректальным раком с метастатическим поражением печени. Тазовая хирургия и онкология. 2011; (1): 32–40. DOI: 10.24412/Fhr0i8_-Ots.

[5] Sekacheva M.I., Po­lishchuk L.O., Bagmet N.N., Skipenko O.G. Results of surgical treatment of metastatic colorectal cancer after drug therapy with bevacizumab. Journal of modern oncology. 2012; 14 (2): 38–41.(In Russ.)

[6] Секачёва М.И., Полищук Л.О., Багмет Н.Н., Скипенко О.Г. Результаты хирургического лечения метастатического колоректального рака после проведения лекарственной терапии с добавлением бевацизумаба. Соврем. онкол. 2012; 14 (2): 38–41.

[7] Zorina E.Yu., Orlova R.V. Prognostic factors of tumoral process in patients with disseminated colorectal cancer. Tazovaya khi­rurgiya i onkologiya. 2014; (2): 33–40. (In Russ.) DOI: 10.17650/2220-3478-2014-0-2-33-40.

[8] Зорина Е.Ю., Орлова Р.В. Прогностические факторы опухолевого процесса у больных диссеминированным колоректальным раком. Тазовая хирургия и онкология. 2014; (2): 33–40. DOI: 10.17650/2220-3478-2014-0-2-33-40.

[9] Falcone A., Ricci S., Brunetti I. et al. Phase III ­trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 2007; 25: 1670–1676. DOI: 10.1200/JCO.2006.09.0928.

[10] Klinger M., Tamandl D., Eipeldauer S. et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann. Surg. Oncol. 2010; 17: 2059–2065. DOI: 10.1245/s10434-010-0972-9.

[11] Tournigand C., Cervantes A., Figer A. et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced co­lorectal cancer — a GERCOR study. J. Clin. Oncol. 2006; 24: 394–400. DOI: 10.1200/JCO.2005.03.0106.

[12] Ychou M., Hohenberger W., Thezenas S. et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann. Oncol. 2009; 20: 1964–1970. DOI: 10.1093/annonc/mdp236.

[13] Ychou M., Viret F., Kramar A. et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemoth. Pharmacol. 2008; 62: 195–201. DOI: 10.1310/hpj4607-482.

[14] Bessmeltsev S.S., Romanenko N.A. Anemiya pri opukholevykh zabolevaniyakh sistemy krovi. Rukovodstvo dlya vrachey. (Anemia in tumor diseases of the blood system. Hands. for doctors.) Moscow: SIMK. 2017; 228 p. (In Russ.)

[15] Бессмельцев С.С., Романенко Н.А. Анемия при опухолевых заболеваниях системы крови. Руководство для врачей. М.: СИМК. 2017; 228 с.

[16] Glazanova T., Rozanova O., Romanenko N. Influence of inflammatory cytokines on genesis of anemia in lymphoproliferative disorder’s patients. In: Hemasphere. The abstract book of the 23th Congress of the European Hematology Association (EHA-23). 2018; 2 (s1): 896.

[17] Romanenko N.A., Bessmeltsev S.S., Albo­rov A.E. et al. Aspects of the pathogenesis of anemia in cancer patients. Kazan medical journal. 2019; 100 (6): 950–957. (In Russ.) DOI: 10.17816/KMJ2019-950.

[18] Романенко Н.А., Бессмельцев С.С., Алборов А.Э. и др. Аспекты патогенеза анемии у пациентов онкологического профиля. Казанский мед. ж. 2019; 100 (6): 950–957. DOI: 10.17816/KMJ2019-950.

[19] Protokoly klinicheskikh rekomendatsiy podderzhiva­yushchey terapii v onkologii. (Protocols of clinical recommendations for supportive therapy in Oncology.) Ed. by M.I. Davydov. 2nd edition, revised and enlarged. Moscow. 2018; 228 p. www.rassc.org (access date: 17.04.2020). (In Russ.)

[20] Протоколы клинических рекомендаций поддерживающей терапии в онкологии. Под. ред. М.И. Давыдова. 2-е издание, переработанное и дополненное. М. 2018; 228 с. www.rassc.org (дата обращения: 17.04.2020).

RIGHTS & PERMISSIONS

Alborov A.E., Hanevich M.D., Bessmeltsev S.S., Rozanova O.E., Glazanova T.V., Romanenko N.A.